Therapy for cytomegalovirus retinitis: still no silver lining
Article Abstract:
New therapies are needed for cytomegalovirus retinitis. This eye disease occurs when the cytomegalovirus damages the retina. It occurs in one-third of AIDS patients and can lead to blindness. Ganciclovir and foscarnet are the only approved drugs to treat this condition. However, they can not eliminate the virus completely. A 1996 study of each drug used separately and in combination found that combination therapy controlled the progression of the disease but did not improve visual acuity. Almost half the patients changed from combination therapy to therapy with one drug or the other due to side effects. Combination therapy also costs more and requires longer infusion times. New drugs that are injected into the eye and sustained-release drugs may improve the outcome of this disease. Researchers are testing antibodies that eliminate the virus. AIDS patients should have regular eye exams by an experienced ophthalmologist.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Therapeutic options for resistant cytomegalovirus retinitis
Article Abstract:
A combination of therapies will probably be needed to halt the progression of cytomegalovirus retinitis in AIDS patients. Cytomegalovirus retinitis is an infection of the retina caused by cytomegalovirus. Intravenous ganciclovir and foscarnet are the most commonly used drugs to treat the disease, but they may not prevent recurrences. In addition, the virus may become resistant to the drugs. Newer techniques include injecting the drug directly into the eye and implanting a sustained release device in the eye.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
Better treatment for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome
Article Abstract:
AIDS patients taking foscarnet for cytomegalovirus (CMV) retinitis survived an average of 12 months, compared to an average of eight months for those taking ganciclovir.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1992
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. New therapies for cytomegalovirus retinitis
- Abstracts: Transforming Medicare: House passes GOP bill; action shifts to Senate. House-Senate panel may do battle over physician-friendly Medicare provisions
- Abstracts: Walking the auditor's gangplank: IG investigates overbilling at teaching hospitals. Grants encourage med schools to add spiritual training
- Abstracts: Risk factors for infusion-related phlebitis with small peripheral venous catheters: a randomized controlled trial
- Abstracts: Miami medical school leads the way in assisting Haitians while training family medicine residents. Military physicians lend healing hands to Haiti